Obesity drug discarded after being tied to patient deaths

John Gregory | | Health Exec | Economics

Boston-based biotech company Zafgen has scrapped plans to bring binge-eating disorder treatment beloranib to market after two patients in clinical trials died after developing blood clots in their lungs.

The Food and Drug Administration placed the trials on hold, and Zafgen has decided it would be cost prohibitive to restart them, so it’s laying off a third of its staff and focusing on other research.

For more on what went wrong with a once-promising treatment, click on the link below: 

https://www.statnews.com/2016/07/19/zafgen-obesity-deaths/

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Report: 44% of adults in the U.S. are uninsured or underinsured
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation
Cardiologist demand is on the rise—can hospitals keep up?
Cardinal Health scoops up two companies for $3.9B
UnitedHealth defends $3.3B Amedisys acquisition
DOJ sues to block UnitedHealth’s $3.3B acquisition of home health giant

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”